Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
HFpEF outcomes were improved with semaglutide, compared with placebo, among patients with obesity-related HFpEF and type 2 diabetes.
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
For the first time a semaglutide weight loss drug has been approved for use in Australia to also treat cardiovascular disease ...
A new study increases max-dose guidance for semaglutide. This offers hope for those who didn’t reach their weight goals. The ...
For the first time in Australia, a weight loss drug has been approved to also treat cardiovascular disease in overweight and obese patients. The ...
Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...
In addition, 40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with ...
In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results